Platform
Home
Screener
Copilot
AskEdgar Studio
New
Back
Seres Therapeutics, Inc.
MCRB · SEC Filings
website
66
Seres Therapeutics, Inc. is a pioneering microbiome therapeutics firm dedicated to engineering bacte...
Price
1.7
Market Cap
17.33 M
Float
7.91 M
Country
US
Sector
Healthcare
Exchange
NASDAQ
Overview
Filings
Insights
Dilution
News
Transcripts
Search in Documents
Open in Studio
Studio
Login
Ask about MCRB
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
All
Chronological
Financials
Registrations
Prospectus
News
Proxies
Ownerships
Other
Seres Therapeutics, Inc.
MCRB · SEC Filings
7.91 M
Float
1.7
Price
17.33 M
Market Cap
Financials
TYPE
HEADLINE
FILED AT
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 4, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 5, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 5, 2026
10-K
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 12, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 5, 2025
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 6, 2025
News
TYPE
HEADLINE
FILED AT
Prospectus
TYPE
HEADLINE
FILED AT
424B5
OFFERING - OTHER | Offering amount: $500,001 | Shares: 103,520 | Price: $4.830
Aug 4, 2026
424B3
UPDATED
Oct 11, 2024
424B5
SHELF OFFERING | Shares amount: 31,746,030 | Share price: $3.15 | Offering amount: $99,999,994.50
Jun 30, 2022
424B5
ATM | Offering amount: $150,000,000
May 21, 2021
424B5
959,002 Shares
Aug 14, 2020
424B5
10,500,000 Shares
Aug 14, 2020
Registrations
TYPE
HEADLINE
FILED AT
Proxies
TYPE
HEADLINE
FILED AT
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 27, 2026
DEF 14A
Form DEF 14A - Other definitive proxy statements
Apr 27, 2026
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 3, 2025
DEF 14A
Form DEF 14A - Other definitive proxy statements
Mar 13, 2025
PRE 14A
Form PRE 14A - Other preliminary proxy statements
Mar 3, 2025
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Sep 12, 2024
Ownerships
TYPE
HEADLINE
FILED AT
4
Brady Kelly (Reporting)
Aug 18, 2026
4
Shaff Eric D. (Reporting)
Aug 18, 2026
4
Henn Matthew R (Reporting)
Aug 18, 2026
4
DesRosier Thomas (Reporting)
Aug 18, 2026
S-3
Form S-3 - Registration statement under Securities Act of 1933
Aug 13, 2026
4
Graves Kurt (Reporting)
Jul 10, 2026
Chronological
TYPE
HEADLINE
FILED AT
Other
TYPE
HEADLINE
FILED AT
EFFECT
Form EFFECT - Notice of Effectiveness
Aug 24, 2026
EFFECT
Form EFFECT - Notice of Effectiveness
Oct 15, 2024
CORRESP
Form CORRESP - Correspondence
Oct 9, 2024
LETTER
Form UPLOAD - SEC-generated letter
Oct 8, 2024
EFFECT
Form EFFECT - Notice of Effectiveness
Aug 16, 2023
CORRESP
Form CORRESP - Correspondence
Aug 11, 2023
